|
Zoletil 100
|
-
|
V/NRP/07/1711
|
Virbac S.A., Francija
|
QN01AX99
|
dogs; cats
|
|
Medicinal product information
| Pharmaceutical form: |
lyophilisate and solvent for solution for injection
|
| International name (active substance): |
Zolazepam hydrochloride, Tiletamine hydrochloride
|
| Distribution category: |
To be used only by veterinary surgeon
|
| Manufacturer(s) responsible for batch release |
Virbac S.A., Francija
|
| Date of authorisation/renewal: |
15-Jan-2013
|
| Marketing authorisation valid until: |
Unlimited time period
|
| Marketing authorisation procedure: |
NRP
|
| Package leaflet: |
[DOCX] 11112025LI (11-Nov-2025)
|
| Labelling text: |
[DOCX] 11112025M (11-Nov-2025)
|
| Summary of product characteristics: |
[DOCX] 11112025ZA (11-Nov-2025)
|
Products
| ID |
Strength |
Package size |
Primary packaging |
Labelling |
| V/NRP/07/1711-01 |
|
1 |
Flakons (šķīdinātājs), 5 ml;Flakons (liofilizāts), 970 mg |
-
|
|
|
Zoletil 50
|
-
|
V/NRP/07/1710
|
Virbac S.A., Francija
|
QN01AX99
|
dogs; cats
|
Vairāk
|
Medicinal product information
| Pharmaceutical form: |
lyophilisate and solvent for solution for injection
|
| International name (active substance): |
Tiletamine hydrochloride,Zolazepam hydrochloride
|
| Distribution category: |
To be used only by veterinary surgeon
|
| Manufacturer(s) responsible for batch release |
Virbac S.A., Francija
|
| Date of authorisation/renewal: |
15-Jan-2013
|
| Marketing authorisation valid until: |
Unlimited time period
|
| Marketing authorisation procedure: |
NRP
|
| Package leaflet: |
[DOC] 270323LI (27-Mar-2023)
|
| Labelling text: |
[DOC] 270323M (27-Mar-2023)
|
| Summary of product characteristics: |
[DOC] 270323ZA (27-Mar-2023)
|
Products
| ID |
Strength |
Package size |
Primary packaging |
Labelling |
| V/NRP/07/1710-01 |
|
1 |
Flakons (šķīdinātājs), 5 ml;Flakons (liofilizāts), 675 mg |
-
|
|